News
Early-stage financing rounds are on track to hit their lowest dollar value in years as funders continue to eschew risky investments, experts told BioSpace.
FEATURED STORIES
After debuting on the public markets with $256.3 million and raking in an additional $472 million, Veradermics has emerged as one of biotech’s biggest post-IPO standouts. CEO Reid Waldman credits the weight loss craze for establishing consumer-driven channels.
Molecular glue degraders are gaining traction in the clinic as well as funding from Big Pharma, with their potential to treat previously “undruggable” cancers and immunological diseases. Here are five clinical programs worth keeping an eye on.
Last month, the FDA launched TrialBlazer, intended to streamline the IND path and bring early clinical trials and medical innovation home to the U.S. It’s a start, but new agency leadership must see it through.
FROM OUR EDITORS
Read our takes on the biggest stories happening in the industry.
Congressional letters sent to the CEOs of Eli Lilly, Pfizer, Merck, BMS and AbbVie this week voicing concerns about the pharmas’ clinical trials in China highlight an ongoing discrepancy in how government and industry think about the rise of the Asian country’s biotech industry.
THE LATEST
As Martin Shkreli, Elizabeth Holmes and Sunny Balwani, and the Purdue bankruptcy deal play out, there is even more drama beyond the stories–a failure to pay legal fees.
Halozyme Therapeutics announced that it is acquiring Antares Pharma for $960 million in cash. The news caused Antares stock to rocket 47% in premarket trading.
Vertex has made a point over the past decade to make research and development a priority, investing over 70% of its expenses back into it.
“I want to put together cures for AstraZeneca and patients,” Matthew Ellis, the company’s new SVP of early oncology told BioSpace in an interview.
Cimeio Therapeutics, a novel cell therapy startup, announced the completion of a $50 million Series A financing round Wednesday morning.
Even if you aren’t looking for a new role in biopharma, nurturing relationships will only benefit you in the long run. To help, here is a complete guide to networking in the life science industry.
Myovant said that the FDA provided notice it had found deficiencies that will preclude any potential discussion of labeling or post-marketing requirements at this time.
The funding will be used to push forward Aurion’s cell therapy program for corneal edema secondary to endothelial dysfunction.
Hundreds of presentations on oncology research are highlighted at the AACR Annual Meeting, which is running from April 7 to 13 in New Orleans.
Kirstin Bibbins-Domingo takes over on July 1 and will become the first African American to helm the prestigious medical journal.